Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 7/2017

07.04.2017 | Retinal Disorders

The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study

verfasst von: Thomas Bertelmann, Joachim Wachtlin, Stefan Mennel, Michael J. Koss, Mathias M. Maier, Ricarda G. Schumann, Sara Kazerounian, Hanna Daniel, Steffen Schmitz-Valckenberg, on behalf of the EXPORT study group

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the agreement and predictability of ocriplasmin treatment effects among retinal experts (raters) by assessment of retinal imaging data of eyes treated for vitreomacular traction in nine different centers in Germany and Austria.

Methods

Retrospective cohort study. Combined confocal near-infrared scanning laser ophthalmoscopy and spectral-domain optical coherence tomography images (Spectralis® device, Heidelberg Engineering GmbH, Germany) from 136 eyes of 135 subjects were reviewed by 14 raters using an internet-based grading database and a standardized questionnaire. In addition to the images taken within 2 days prior to treatment, age, gender, and lens status were disclosed to the raters. Treatment success was defined as a complete cleavage of the posterior vitreous cortex at day 28±5. Main outcome was the agreement and predictability among raters for assessment of treatment success.

Results

Raters generally accepted starting ocriplasmin treatment (chance for treatment success ≥ 1%) in 22.4 to 69.1% (median 53.2%) of eyes (moderate intra- and interrater agreements with kappa-values of 0.6 and 0.48). The likelihood for a high potential treatment success (equal or higher than 25%) was judged by the raters in 43.4% to 86.0% (median 62.6%) of eyes (moderate intra- and fair interrater agreements with kappa-values of 0.56 and 0.22). Allocating eyes for high potential treatment success overall increased the odds by 3.07, with odds ratios of single raters up to 4.06 to 6.16.

Conclusions

These results underscore the importance of training health care providers in the evaluation of retinal imaging data and also to define characteristic morphological features better in the presence of vitreoretinal interface diseases. The better results of single raters in the predictability of treatment success by the allocation of eyes in the high-potential group indicates the high relevance of the meticulous analysis of retinal images.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat García-Layana A, García-Arumí J, Ruiz-Moreno JM, Arias-Barquet L, Cabrera-López F, Figueroa MS (2015) A review of current management of vitreomacular traction and macular hole. J Ophthalmol 2015:809640. doi:10.1155/2015/809640 PubMedPubMedCentral García-Layana A, García-Arumí J, Ruiz-Moreno JM, Arias-Barquet L, Cabrera-López F, Figueroa MS (2015) A review of current management of vitreomacular traction and macular hole. J Ophthalmol 2015:809640. doi:10.​1155/​2015/​809640 PubMedPubMedCentral
5.
Zurück zum Zitat Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands: Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: Therapeutische Strategien. www.dog.org (Accessed on 06 Apr 2016) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands: Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: Therapeutische Strategien. www.​dog.​org (Accessed on 06 Apr 2016)
6.
Zurück zum Zitat Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA, Group M-TS (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615. doi:10.1056/NEJMoa1110823 CrossRefPubMed Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA, Group M-TS (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615. doi:10.​1056/​NEJMoa1110823 CrossRefPubMed
7.
Zurück zum Zitat Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, Kampik A, Jaffe GJ, Toth CA, Group M-TS (2015) Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 122:117–122. doi:10.1016/j.ophtha.2014.07.045 CrossRefPubMed Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, Kampik A, Jaffe GJ, Toth CA, Group M-TS (2015) Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 122:117–122. doi:10.​1016/​j.​ophtha.​2014.​07.​045 CrossRefPubMed
8.
Zurück zum Zitat Chatziralli I, Theodossiadis G, Parikakis E, Datseris I, Theodossiadis P (2015) Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-015-3031-1 Chatziralli I, Theodossiadis G, Parikakis E, Datseris I, Theodossiadis P (2015) Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Graefes Arch Clin Exp Ophthalmol. doi:10.​1007/​s00417-015-3031-1
9.
Zurück zum Zitat Yamamoto S, Yamamoto T, Ogata K, Hoshino A, Sato E, Mizunoya S (2004) Morphological and functional changes of the macula after vitrectomy and creation of posterior vitreous detachment in eyes with diabetic macular edema. Doc Ophthalmol 109:249–253CrossRefPubMed Yamamoto S, Yamamoto T, Ogata K, Hoshino A, Sato E, Mizunoya S (2004) Morphological and functional changes of the macula after vitrectomy and creation of posterior vitreous detachment in eyes with diabetic macular edema. Doc Ophthalmol 109:249–253CrossRefPubMed
10.
Zurück zum Zitat Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C (2015) Efficacy of Intravitreal Ocriplasmin on Vitreomacular Traction and Full-Thickness Macular Holes. Am J Ophthalmol. doi:10.1016/j.ajo.2015.01.034 Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C (2015) Efficacy of Intravitreal Ocriplasmin on Vitreomacular Traction and Full-Thickness Macular Holes. Am J Ophthalmol. doi:10.​1016/​j.​ajo.​2015.​01.​034
11.
Zurück zum Zitat Maier M, Abraham S, Frank C, Feucht N, Lohmann CP (2015) Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole: First clinical experiences. Ophthalmologe. doi:10.1007/s00347-015-0073-z Maier M, Abraham S, Frank C, Feucht N, Lohmann CP (2015) Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole: First clinical experiences. Ophthalmologe. doi:10.​1007/​s00347-015-0073-z
12.
Zurück zum Zitat Lommatzsch AP, Gutfleisch M, Dietzel M, Heimes B, Spital G, Böhme M, Bornfeld N, Pauleikhoff D (2014) Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin. Klin Monbl Augenheilkd 231:909–914. doi:10.1055/s-0034-1368372 CrossRefPubMed Lommatzsch AP, Gutfleisch M, Dietzel M, Heimes B, Spital G, Böhme M, Bornfeld N, Pauleikhoff D (2014) Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin. Klin Monbl Augenheilkd 231:909–914. doi:10.​1055/​s-0034-1368372 CrossRefPubMed
13.
14.
Zurück zum Zitat Mennel S (2014) Enzymatic vitreolysis – from clinical trials to clinical practice. Spektrum Augenheilkd. 28:59–60 Mennel S (2014) Enzymatic vitreolysis – from clinical trials to clinical practice. Spektrum Augenheilkd. 28:59–60
15.
Zurück zum Zitat Singh RP, Li A, Bedi R, Srivastava S, Sears JE, Ehlers JP, Schachat AP, Kaiser PK (2014) Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 98:356–360. doi:10.1136/bjophthalmol-2013-304219 CrossRefPubMed Singh RP, Li A, Bedi R, Srivastava S, Sears JE, Ehlers JP, Schachat AP, Kaiser PK (2014) Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 98:356–360. doi:10.​1136/​bjophthalmol-2013-304219 CrossRefPubMed
18.
Zurück zum Zitat Yamamoto T, Akabane N, Takeuchi S (2001) Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 132:369–377CrossRefPubMed Yamamoto T, Akabane N, Takeuchi S (2001) Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 132:369–377CrossRefPubMed
19.
Zurück zum Zitat Yamamoto T, Kamei M, Kunavisarut P, Suzuki M, Tano Y (2008) Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model. Graefes Arch Clin Exp Ophthalmol 246:509–514. doi:10.1007/s00417-007-0670-x CrossRefPubMed Yamamoto T, Kamei M, Kunavisarut P, Suzuki M, Tano Y (2008) Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model. Graefes Arch Clin Exp Ophthalmol 246:509–514. doi:10.​1007/​s00417-007-0670-x CrossRefPubMed
20.
Zurück zum Zitat Paul C, Heun C, Müller HH, Fauser S, Kaymak H, Kazerounian S, Sekundo W, Mennel S, Meyer CH, Schmitz-Valckenberg S, Koss MJ, Feltgen N, Bertelmann T (2016) IMPACT OF VITREORETINAL INTERFACE ARCHITECTURE ON SUCCESSFUL VITREOMACULAR TRACTION RESOLUTION IN EYES SCHEDULED FOR INTRAVITREAL OCRIPLASMIN THERAPY. Retina. doi:10.1097/IAE.0000000000001371 Paul C, Heun C, Müller HH, Fauser S, Kaymak H, Kazerounian S, Sekundo W, Mennel S, Meyer CH, Schmitz-Valckenberg S, Koss MJ, Feltgen N, Bertelmann T (2016) IMPACT OF VITREORETINAL INTERFACE ARCHITECTURE ON SUCCESSFUL VITREOMACULAR TRACTION RESOLUTION IN EYES SCHEDULED FOR INTRAVITREAL OCRIPLASMIN THERAPY. Retina. doi:10.​1097/​IAE.​0000000000001371​
21.
Zurück zum Zitat Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P (2013) The international vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120:2611–2619. doi:10.1016/j.ophtha.2013.07.042 CrossRefPubMed Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P (2013) The international vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120:2611–2619. doi:10.​1016/​j.​ophtha.​2013.​07.​042 CrossRefPubMed
22.
Zurück zum Zitat Mastropasqua R, Di Antonio L, Ciciarelli V, Aharrh-Gnama A, Rispoli M, Carpineto P (2016) Comparison of Guided and Unguided Ocriplasmin Injection for the Treatment of Vitreomacular Traction: A Preliminary Study. J Ophthalmol 2016:6521304. doi:10.1155/2016/6521304 CrossRefPubMedPubMedCentral Mastropasqua R, Di Antonio L, Ciciarelli V, Aharrh-Gnama A, Rispoli M, Carpineto P (2016) Comparison of Guided and Unguided Ocriplasmin Injection for the Treatment of Vitreomacular Traction: A Preliminary Study. J Ophthalmol 2016:6521304. doi:10.​1155/​2016/​6521304 CrossRefPubMedPubMedCentral
Metadaten
Titel
The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study
verfasst von
Thomas Bertelmann
Joachim Wachtlin
Stefan Mennel
Michael J. Koss
Mathias M. Maier
Ricarda G. Schumann
Sara Kazerounian
Hanna Daniel
Steffen Schmitz-Valckenberg
on behalf of the EXPORT study group
Publikationsdatum
07.04.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 7/2017
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3657-2

Weitere Artikel der Ausgabe 7/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 7/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.